Our vision is for CardioWise to become the recognized global provider of the best available heart health analysis products. These products will become the new gold standard of care through their ability to provide unprecendented detail on patients' whole heart health.

CardioWise's first product is its MPS™ heart analysis software. MPS is capable of quantitatively assessing the contractile function of the left ventricle using tagged-MRI data. Individual patient data is compared to a normalized database of healthy heart data to eliminate subjectivity of diagnosis using an easy-to-read graphic report. No competing technique can provide the finely detailed, quantitative information that is critical to making good treatment decisions and monitoring treatment progress.

Technology Solutions for Better Heart Health

Heart disease is the leading cause of death in the United States. Each year, an estimated 1.5 million people in the U.S. suffer myocardial infarctions, more commonly known as heart attacks. Dramatic improvements in available drug treatments and surgical interventions for heart disease are available. However these therapies are dependent on the ability of physicians to interpret a battery of diagnostic imaging tests, none of which is quantitative or conclusive. There would be more benefit from appropriate therapies if heart problems could be diagnosed earlier and more accurately. Currently, however, no single diagnostic test is available that can provide an evaluation of all three major heart components: coronary arteries, myocardium, and valves. CardioWise is commercializing patent-pending, non-invasive Cardiac Magnetic Resonance Imaging (cMRI) analysis software that produces a quantified 3D image model of the human heart, called Multiparametric Strain (MPS™) heart analysis. CardioWise heart analysis software combined with cardiac MRI is a single diagnostic test that is able to provide quantitative analysis of the myocardium, arteries, and valves with an unprecedented level of detail. It has the opportunity to become the new gold standard of care for heart health analysis.

CardioWise's patent pending MPS system can be used to quantitatively assess cardiovascular health. This detailed information can help with surgery decisions, or provide information so doctors can help patients avoid heart failure. No other technique is able to give as detailed, in-depth information. MPS allows better treatment decision-making and quantitative monitoring of treatment progress.

Top:
Examples of normal heart left ventricles.

Middle and bottom:
Examples of interior myocardial infarctions. Blue is indicative of healthy tissue and red indicates significant damage.